Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
13. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
14. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
15. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
16. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
17. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
18. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
19. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
20. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
21. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
22. The pharmaceutical composition of claim 12 , wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.